Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPC1001 in Essential Hypertension
NCT06826872Phase 2Recruiting
- Sponsor
- Shinpoong Pharma
- Start
- Jun 2024
- Primary completion
- Oct 2025
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of candesartan, amlodipine and indapamide in essential hypertension (4 arms), sponsored by Shinpoong Pharma. Primary endpoint: Change in Mean Sitting Systolic Blood Pressure at 8 weeks. Started Jun 2024; status: recruiting.
02
Drugs
candesartanamlodipineindapamide
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT06826872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06826872.